Clinical trialNCT00929591CompletedPhase 3Interventional

SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

SponsorSWOG Cancer Research NetworkEnrollment1,558Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving tamoxifen alone is more effective in treating breast cancer than giving tamoxifen together with chemotherapy or after chemotherapy. PURPOSE: This randomized phase III trial is studying giving tamoxifen with or without combination chemotherapy to compare how well they work in treating postmenopausal women who have undergone surgery for breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Charles D. Cobau, MD
Flower Hospital Cancer Center
Study Chair
clinicaltrials.gov ↗
Ellis G. Levine, MD
Roswell Park Cancer Institute
Study Chair
clinicaltrials.gov ↗
James N. Ingle, MD
Mayo Clinic
Study Chair
clinicaltrials.gov ↗
Kathleen I. Pritchard, MD
Toronto Sunnybrook Regional Cancer Centre
Study Chair
clinicaltrials.gov ↗
Kathy S. Albain, MD
Loyola University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Doxorubicin →Endocrine therapyEndocrine-modulating drug therapyFluorouracil →Tamoxifen →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 1989
Primary completion: 31 Aug 2005
Completion: 31 Mar 2010
Last update posted: 24 Jan 2013
Registered enrollment: 1,558
Registry id: NCT00929591

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.